A reader — I’ll call him Jack — recently asked my thoughts on his plans to pursue treatment with lecanemab for his mild cognitive impairment caused by Alzheimer’s disease. So we set up a call to discuss what it is like to live beset by the threat of Alzheimer’s disease, but also the promise of a treatment to slow it.
Jack’s account of his neurologist’s workup and the many steps from diagnosis to anti-amyloid therapy seemed in order. As we explored the details, however, something felt out of order. The problem wasn’t what I was hearing; it was what I wasn’t hearing.
A very important character was missing.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
